

# INVESTOR FACTSHEET

FOR THE YEAR ENDED 31 DECEMBER 2025

د. سليمان الحبيب  
DR SULAIMAN AL HABIB  
المجموعة الطبية medical group




## FINANCIAL INDICATORS



Million

### REVENUE BY SEGMENT



### REVENUE


13,707

+22%

CAGR 17.26%



Million



### NET PROFIT


2,401

+4%

CAGR 14.93%



Million



### EBITDA


3,507

+18%

CAGR 17.39%



Million



### DIVIDENDS


1,691

+1%

CAGR 14.60%



Million



All figures are rounded to the nearest SR million unless otherwise specified

# INVESTOR FACTSHEET

FOR THE YEAR ENDED 31 DECEMBER 2025

د. سليمان الحبيب  
DR SULAIMAN AL HABIB  
المجموعة الطبية medical group



## FINANCIAL INDICATORS

### STATEMENT OF FINANCIAL POSITION HIGHLIGHTS

#### TOTAL ASSETS


**23,205**

▲ +13%

CAGR 20.99%



Million



#### SHAREHOLDERS' EQUITY


**7,902**

▲ +10%


CAGR 10.30%




Million



### TOTAL ASSETS AS OF 31<sup>st</sup> DECEMBER



### CASH FLOW HIGHLIGHTS



All figures are rounded to the nearest  $\text{S.A.}$  million unless otherwise specified

# INVESTOR FACTSHEET

FOR THE YEAR ENDED 31 DECEMBER 2025

د. سليمان الحبيب  
DR SULAIMAN AL HABIB  
المجموعة الطبية medical group



## FINANCIAL INDICATORS

### FINANCIAL & OPERATING HIGHLIGHTS

#### CAPEX


**2,983**

▼ (22%)

CAGR 24.21%



Million




#### PATIENTS

**9.46**


▲ +28%

CAGR 20.93%

Million



	FY-21	FY-22	FY-23	FY-24	FY-25
Profit %	18.99%	19.86%	21.52%	20.67%	17.52%
EBITDA %	25.47%	25.70%	26.62%	26.57%	25.59%
ROE %	26.86%	29.43%	33.10%	33.90%	31.86%
ROA %	13.56%	14.10%	14.42%	12.74%	10.97%
Payout %	71.19%	73.78%	73.90%	72.11%	70.39%
EPS ₪	3.93	4.72	5.85	6.62	6.86



#### WORKING CAPITAL

Receivables



Inventory



Payables



Cash Conversion Cycle

(2) Day

CAGR 5 yrs

● (4.9%)

● 5.6%


● 8.7%

●

#### FINANCIAL LEVERAGE

D/E

DSCR



HEALTHCARE FACILITIES **23**

2024: 18 Healthcare Facilities



BEDS **+4,000**

2024: +3,300 Beds



PHARMACIES **44**

2024: 35 Pharmacies



PAYROLL STAFF # **+25.6K**

2024: +20.9K Payroll Staff

All figures are rounded to the nearest ₪ million unless otherwise specified



## INVESTOR RELATIONS ENQUIRIES

Investor Relations Department  
Dr. Sulaiman Al Habib Medical Services Group  
Tel: +966 11 5259999 Ext: 4919  
Email: [investor.relations@drsulaimanalhabib.com](mailto:investor.relations@drsulaimanalhabib.com)  
P.O. Box 301578 Riyadh 11372, Kingdom of Saudi Arabia



Scan  
barcode to  
visit our IR  
website

## DISCLAIMER

### Disclaimer and important information in relation to this presentation

The information in this fact sheet ("Fact Sheet") has been prepared for general use purposes only, and is not necessarily comprehensive as it has not been independently verified, neither is it considered or constitutes part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or solicitation to buy or subscribe for any Securities in the Kingdom of Saudi Arabia ("KSA"), and does not constitute an offer, invitation or recommendation in connection with purchase, ownership or sale of any securities of Dr. Sulaiman Al Habib Medical Services Group Company (the "Company" or "HMG") and no warranty, express or implied, is made as to the accuracy, completeness, or correctness of the information or opinions contained in this Fact Sheet by the Company, and no person or legal entity should rely for any purpose on the information contained in this Fact Sheet .

Any assumptions, views or opinions contained in this Fact Sheet represent the assumptions, views or opinions of the Company as of the date indicated and are subject to change without notice, and information contained in this Fact Sheet related to past performance is not an indication of future performance, and is not intended to predict actual results, and no assurances are given with respect thereto.

This Fact Sheet may include statements that are or may be considered "forward-looking statements" regarding the Company's financial position, results of operations and business, and certain of the HMG's plans, expectations, assumptions, and objectives, which are for general update only and do not constitute an invitation or inducement to engage in any investment activity; It does not constitute an offer or invitation to buy or subscribe to any securities in the KSA and does not constitute an offer, invitation or recommendation in connection with purchase, ownership or sale of any securities of HMG. The information contained in this Fact Sheet, including but not limited to forward-looking statements, is current as of the date of this Fact Sheet and is not intended to provide any assurances about future outcomes. HMG expressly releases itself from any obligation or undertaking to publish any updates or revisions to this Fact Sheet, including financial statements or forward-looking statements, that may arise as a result of the emergence of new information or the occurrence of future events or otherwise, unless required by applicable laws and regulations. This Fact Sheet should not be construed by anyone as financial, tax, or investment advice. Neither HMG nor any of its directors or employees shall be liable for any direct or indirect loss or damage that any person may incur as a result of relying on this Fact Sheet including the forward-looking statements.